Listed by the USPTO as CANDELARIA, JULIANA IRENE
Tech Center 1600 • Art Units: 1600 1633 1634 1641 1674 1677
This examiner grants 0% of resolved cases
CANDELARIA, JULIANA IRENE handles art unit 1600 in tech center 1600. The profile contains 3 resolved cases, a 0.0% allowance rate, and a 0.0% interview lift. The median days to allowance are 1122.
The listed companies are Regeneron Pharmaceuticals Inc., Ricoh Company, Ltd., and Janssen Pharmaceuticals Inc. The listed firms are Morgan, Lewis & Bockius LLP (WA), BakerHostetler, and BAUMGARTNER PATENT LAW. The limited record does not show an allowance or interview-associated benefit, so practitioners should rely on detailed review of the individual application rather than broad inferences.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18717851 | Method of Production of Organoids and Uses Thereof | Non-Final OA | Centre National de la Recherche Scientifique |
| 18854168 | METHODS AND MATERIALS FOR TREATING SYNGAP1-ASSOCIATED NEURODEVELOPMENTAL DISORDERS | Non-Final OA | The Johns Hopkins University |
| 18733979 | HYDROGEL, INKJET INK, METHOD FOR PRODUCING CELL CULTURE BODY, AND CELL-CONTAINING GEL PARTICLES AND METHOD FOR PRODUCING SAME | Non-Final OA | RICOH COMPANY, LTD. |
| 18714931 | NEUROPROTECTIVE AGENTS FOR USE IN THE TREATMENT OF OPTIC NEUROPATHIES | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 18115285 | BIOREACTOR FOR ANTIBODY PRODUCTION | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 18846524 | NOVEL ANELLOVIRIDAE FAMILY VECTOR COMPOSITIONS AND METHODS | Non-Final OA | FLAGSHIP PIONEERING INNOVATIONS V, INC. |
| 15550951 | MATERIALS AND METHODS FOR TREATMENT OF HEMOGLOBINOPATHIES | Final Rejection | William Marsh Rice University |
| 18645616 | Rotator Cuff Therapy Using Muscle Fiber Fragments | Non-Final OA | Wake Forest University Health Sciences |
| 18750252 | Composition for Culturing Animal Cells | Non-Final OA | AJINOMOTO CO., INC. |
| 17996573 | SIRPa Deficient Macrophages for Treating Cancer | Final Rejection | Georgia State University Research Foundation, Inc. |
| 18905388 | METHODS AND MATERIALS FOR GALGT2 GENE THERAPY | Non-Final OA | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy0.0% of resolved applications examined by Juliana Irene Candelaria were allowed (3 resolved cases), compared with 37.3% across Art Unit 1600 over the last five years.
This examiner's interview lift is +0.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Juliana Irene Candelaria took 1,122 days on average from filing to allowance.
Juliana Irene Candelaria examines applications in Art Unit 1600 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
